Literature DB >> 20135633

Plasma homocysteine levels are associated with ulceration of the foot in patients with type 2 diabetes mellitus.

R González1, T Pedro, Jose T Real, S Martínez-Hervás, M R Abellán, R Lorente, A Priego, M Catalá, F J Chaves, J F Ascaso, R Carmena.   

Abstract

BACKGROUND: To examine the association of biochemical markers of risk (plasma Hcy, microalbuminuria, lipoprotein (a)(Lp(a)) and diabetic dyslipidaemia) with the prevalence of diabetic foot ulceration in type 2 diabetic patients.
METHODS: Case/control study conducted in 198 type 2 diabetic patients. 89 patients have foot ulcers and 109 have no foot ulcers (control group), in order to establish ORs for diabetic foot ulceration. In all subjects plasma Hcy, Lp(a), total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein B, HbA(1c) and microalbuminuria were measured using standard procedures.
RESULTS: Plasma Hcy, microalbuminuria, HbA(1c) and apolipoprotein B levels were significantly higher in patients with foot ulceration compared with the control group. Plasma lipids, Lp(a), vitamin B12 and folic acid values were similar in both groups. In the logistic regression model, plasma Hcy (OR 1.09; 95% CI 1.04-1.69), microalbuminuria (OR 1,01; 95% CI 1.01-1.17) and HbA(1c) levels (OR 1.33; 95% CI 1.04-1.69) were independent risk factors for the presence of diabetic foot ulceration.
CONCLUSIONS: In our study, for each micromol increase in plasma Hcy levels there was a 10% increase in the risk of diabetic foot ulceration. In addition, plasma homocysteine, HbA(1c) and microalbuminuria accounted for 50% prevalence risk of diabetic foot ulceration. Further prospective studies should be conducted to confirm the association of plasma Hcy levels with the risk of foot ulceration. Copyright (c) 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20135633     DOI: 10.1002/dmrr.1061

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  5 in total

1.  Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus.

Authors:  Carmine Gazzaruso; Adriana Coppola; Tiziana Montalcini; Elisabetta Baffero; Adriana Garzaniti; Gabriele Pelissero; Silvia Collaviti; Annalisa Grugnetti; Pietro Gallotti; Arturo Pujia; Sebastiano B Solerte; Andrea Giustina
Journal:  Endocrine       Date:  2011-10-11       Impact factor: 3.633

2.  Folic acid may be a potential addition to diabetic foot ulcer treatment - a hypothesis.

Authors:  Mansooreh Bagheri; Behnam Moein Jahromi; Ali Zamani
Journal:  Int Wound J       Date:  2011-08-19       Impact factor: 3.315

3.  Association between Lipid Profile and Apolipoproteins with Risk of Diabetic Foot Ulcer: A Systematic Review and Meta-Analysis.

Authors:  Juan R Ulloque-Badaracco; Melany D Mosquera-Rojas; Enrique A Hernandez-Bustamante; Esteban A Alarcón-Braga; Ricardo R Ulloque-Badaracco; Ali Al-Kassab-Córdova; Percy Herrera-Añazco; Vicente A Benites-Zapata; Adrian V Hernandez
Journal:  Int J Clin Pract       Date:  2022-08-10       Impact factor: 3.149

4.  Vitamin B12 deficiency is associated with adverse lipid profile in Europeans and Indians with type 2 diabetes.

Authors:  Antonysunil Adaikalakoteswari; Ramamurthy Jayashri; Nithya Sukumar; Hema Venkataraman; Rajendra Pradeepa; Kuppan Gokulakrishnan; Ranjit Mohan Anjana; Philip G McTernan; Gyanendra Tripathi; Vinod Patel; Sudhesh Kumar; Viswanathan Mohan; Ponnusamy Saravanan
Journal:  Cardiovasc Diabetol       Date:  2014-09-26       Impact factor: 9.951

5.  Plantar pressure in diabetic peripheral neuropathy patients with active foot ulceration, previous ulceration and no history of ulceration: a meta-analysis of observational studies.

Authors:  Malindu Eranga Fernando; Robert George Crowther; Elise Pappas; Peter Anthony Lazzarini; Margaret Cunningham; Kunwarjit Singh Sangla; Petra Buttner; Jonathan Golledge
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.